<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="170538">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876486</url>
  </required_header>
  <id_info>
    <org_study_id>GPMBC301</org_study_id>
    <nct_id>NCT00876486</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A Open-label, Randomized, Parallel, Phase III Trial to Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol®(Conventional Paclitaxel With Cremorphor EL) in Subjects With Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samyang Biopharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol® in
      subjects with recurrent or metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the efficacy of Genexol®-PM versus Genexol® in subjects with recurrent or metastatic breast cancer based on Objective Response Rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, Progress Free Survival, Time to Tumor Progression, Duration of Overall Response</measure>
    <time_frame>Event driven</time_frame>
    <description>To evaluate the efficacy of Genexol®-PM relative to Genexol® as measured by Overall Survival, Progress Free Survival, Time to Tumor Progression, Duration of Overall Response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity</measure>
    <time_frame>Throughout study</time_frame>
    <description>To compare the safety and toxicity of Genexol®-PM with those of Genexol®</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Genexol®-PM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genexol®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genexol-PM®</intervention_name>
    <description>Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks</description>
    <arm_group_label>Genexol®-PM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genexol®</intervention_name>
    <description>Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks</description>
    <arm_group_label>Genexol®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects should meet all of the following criteria to participate in the trial.

          1. Subjects who aged 18 years or older.

          2. Subjects whose written informed consent was obtained complying with the local
             regulatory requirements prior to their participation in the trial.

          3. Subjects who have histologically or cytologically confirmed breast cancer with
             evidence of recurrence or metastasis.

          4. If subjects have received Taxanes as neo-adjuvant or adjuvant therapy, the subjects
             should have relapsed with breast cancer after 12 months of completing neo-adjuvant or
             adjuvant therapy with Taxanes.

          5. Subjects who have measurable disease in accordance with the RECIST criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si, Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunwoo Park</last_name>
      <phone>82-31-920-1228</phone>
      <phone_ext>1228</phone_ext>
      <email>sophie486@lycos.co.kr</email>
    </contact>
    <investigator>
      <last_name>Jungsil Ro, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>June 10, 2012</lastchanged_date>
  <firstreceived_date>April 3, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
